Aditya Bardia

Academic History

Aditya Bardia, MD, MPH is an Associate Professor of Medicine at Harvard Medical School, Boston, MA and an Attending Physician in Medical Oncology at Massachusetts General Hospital, Boston, MA. He is also the Director of Breast Cancer Research Program at Massachusetts General Hospital.

Dr Bardia obtained his medical degree from the All India Institute of Medical Sciences, New Delhi, India and subsequently obtained an MPH from the University of Iowa College of Public Health, Iowa City, IA. Following this, Dr Bardia completed two residencies in internal medicine at the All India Institute of Medical Sciences and the Mayo Clinic, Rochester, MN, before completing a fellowship at the Johns Hopkins Hospital, Baltimore, MD.

Dr Bardia is the recipient of several awards for his contributions to the field of oncology, including the Young Investigator Award from the ASCO Conquer Cancer Foundation, the Outstanding Award for Research Excellence at the Mayo Clinic, and the Douglas Family Foundation prize for excellence in oncology research at Massachusetts General Hospital.

Speaking on tumor genotyping, CTCs and novel therapeutics for breast cancer

Dr Bardia is involved in the clinical development of tumor genotyping as well as circulating tumor cells (CTCs) to facilitate accurate diagnosis, therapy selection, and real-time monitoring of breast cancer. His research on molecular changes in CTCs in metastatic breast cancer has elucidated the role of epithelial-mesenchymal transition and has provided proof-of-principle that ex-vivo CTC culture and molecular drug testing is feasible in breast cancer. Dr Bardia is also the principal investigator of several clinical trials investigating the role of targeted therapy combinations for breast cancer, such as the development of the first antibody drug conjugate (ADC) sacituzumab govitecan which was approved for the treatment of patients with metastatic triple negative breast cancer.